Hesperidinase encapsulation towards hesperitin production targeting improved bioavailability.

摘要: Hesperidin (hesperitin-7-O-rutinoside) and hesperitin (hesperitin-7-O-glucoside) show anti-inflammatory, antimicrobial, antioxidant, anticarcinogenic effects prevent bone loss. However, hesperidin has a low bioavailability compared to due the rutinoside moiety attached flavonoid. The removal of rhamnose group yield corresponding flavonoid glucoside (hesperetin-7-glucoside) improved aglycone, hesperetin, in humans. In line with these assumptions, aim this work was enzymatic production from hesperidinase. Despite solubility reaction medium, bioconversion carried soluble at lower concentrations (≤0.05 mg ml(-1)) insoluble for high (>0.1-50 ml(-1)). A twofold increase maximum rates overtook expected values, pointing enzyme ability degrade hesperidin. To improve bioprocess, hesperidinase tested immobilized calcium alginate (2%), k-carrageenan chitosan (2%) beads. immobilization out by adsorption encapsulation. Chitosan cross-linked glutaraldehyde (1% 2%) sodium sulfate (13.5% 15%) acetate buffer (0.02 M, pH 4.0). relation between bioprocessing conditions stability studied. residual activity 193% obtained form. half-life 770 min attained encapsulated results presented highlight potential encapsulation towards substrate. our knowledge, presents first time on hydrogels production. This is an important achievement pharmaceutical nutraceutical applications because compound higher